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Background: The aim of this study was to determine whether enteral self-expanding metal stent (SEMS) placement or gastrojejunostomy (GJY) for
palliation of malignant gastric outlet obstruction (GOO) symptoms results in better survival and quality-of-life outcomes.
Methods: This retrospective cohort study included 334 patients who underwent enteral SEMS (n ¼ 241; 56.8% men) or GJY (n ¼ 93; 61.3% men) for
palliation of GOO due to unresectable cancer at our tertiary cancer center between 2001 and 2011. Patient demographic and post-procedure outcome data
were collected.
Results: The mean times to tolerate a liquid diet and a soft diet were signiﬁcantly shorter in the SEMS group (2.2  3.9 days and 4.8  6.2 days,
respectively) than in the GJY group (8.9  5.6 days and 13.6  20.3 days, respectively; P ¼ 0.0001). The mean duration of hospital stay was signiﬁcantly
longer for patients who underwent GJY (17.5  9.5 days) than for patients who underwent SEMS placement (12.3  7.9 days; P < 0.0001). The
complication rate was signiﬁcantly higher for the GJY group (10/93 patients, 10.8%) than for the SEMS group (11/241 patients, 4.6%; P ¼ 0.045). The
reintervention rate was signiﬁcantly higher for the SEMS group (14.9%) than for the GJY group (3.2%, P ¼ 0.002).
Conclusion: Patients who undergo SEMS placement start tolerating an oral diet sooner, have fewer complications, and shorter hospital stays, but have
higher reintervention rates, compared to patients who undergo GJY for palliation of malignant GOO symptoms.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Gastric outlet obstruction (GOO) can result from either a benign
or malignant etiology. Benign GOO etiologies include ulcer- or
radiation-induced strictures. More commonly, GOO occurs in a
malignant setting; pancreatic cancer is the most common, and
others include gastric, duodenal, and hepatocellular cancers,
lymphoma, and metastatic cancers. Depending on the etiology
and/or origin of the primary cancer, GOO can occur at the distal
stomach, pylorus, or duodenum. Patients with malignant GOO
suffer from intractable nausea, vomiting, abdominal pain and
distension, and intolerance to an oral diet. This worsens the
nutritional state of these patients, who are already debilitated due
to cancer-related cachexia. Palliation of such symptoms is of
utmost importance for such patients, not only to improve their
debilitated state but also to enable them to enjoy eating during
their terminal days.1Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD A
2Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX,
3Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Ho
Received 22 August 2013; Revised 13 September 2013; Accepted 13 September 2013
* Corresponding author. Department of Gastroenterology, Hepatology, and Nutrition,
E-mail address: jefﬂee@mdanderson.org (J.H. Lee).
2213-1795/$ – see front matter Copyright  2013, Society of Gastrointestinal Interventi
http://dx.doi.org/10.1016/j.gii.2013.09.008Techniques currently available for palliation of malignant GOO
include surgical procedures such as gastrojejunostomy (GJY) and
endoscopic placement of a duodenal self-expanding metal stent
(SEMS). GJY was the standard treatment to relieve malignant GOO
prior to the introduction of SEMS. It provides symptom relief in
most patients, but is associated with signiﬁcant immediate post-
procedure morbidity and delayed gastric emptying. The introduc-
tion of endoscopic placement of a duodenal SEMS provided an
alternative with faster symptom relief and much lower post-
procedure morbidity. However, recurrent obstructive symptoms
and the need for reintervention are considered to be signiﬁcant
drawbacks of duodenal SEMS.
Several studies, including three randomized controlled trials,1–3
one prospective study,4 and some retrospective studies,5–13 have
compared the outcomes for GJY and duodenal SEMS. The results of
these studies have also been summarized in systematic reviews and
ameta-analysis.14–16 However, all of those studies had small samplenderson Cancer Center, Houston, TX, USA
USA
uston, TX, USA
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
on. Published by Elsevier. All rights reserved.
Table 1 Baseline Characteristics of Patients who Underwent Self-expanding
Metal Stent (SEMS) Placement or Gastrojejunostomy (GJY) for Malignant
Gastric Outlet Obstruction
SEMS GJY P
Age (y) 63.3  11 61.2  12.5 0.27
Sex 0.53
Men 137 (56.8) 57 (61.3)
Women 104 (43.2) 36 (38.7)
Race 0.42
White 171 (71) 71 (76.3)
African American 27 (11.2) 5 (5.4)
Asian 11 (4.6) 5 (5.4)
Hispanic 32 (13.3) 12 (12.9)
Type of cancer 0.07
Pancreatic 133 (55.2) 45 (48.4)
Duodenal 8 (3.3) 11 (11.8)
Papillary 20 (8.3) 9 (9.7)
Stomach 30 (12.4) 4 (4.3)
Others 50 (20.8) 24 (25.8)
Performance status score 0.02
0 5 (3.4) 1 (4.3)
1 48 (32.9) 14 (60.9)
2 74 (50.7) 4 (17.4)
3 17 (11.6) 4 (17.4)




No 73 (30.4) 47 (50.5)
Yes 168 (69.6) 46 (49.5)
Data are presented as n (%) or mean  SD.
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the outcomes for large groups of patients who underwent GJY or
endoscopic SEMS placement for palliation of malignant GOO
symptoms at a tertiary care cancer center during the last 10 years.
Methods
Study design and patient population
In this retrospective cohort study, we included patients with
GOO due to unresectable cancer who underwent GJY or enteral
SEMS placement between 2001 and 2011. Patients with malignant
GOO symptoms who underwent GJY to cure the underlying ma-
lignancy were not included in the study. We reviewed patients’
medical records for demographic data, the type of cancer causing
the GOO, pre-procedure World Health Organization (WHO) per-
formance status score, history of chemo- and radiotherapy, and
type of procedure.
Outcomes
Patients with GOO were classiﬁed into GJY and enteral SEMS
groups. The outcomes compared between the two groups were as
follows: (1) number of days to tolerance of a liquid diet and then a
mechanical soft diet; (2) rate of recurrence of obstructive symp-
toms; (3) rate of reintervention; (4) duration of hospital stay; (5)
complication rate; and (6) survival rate and duration. We also
compared the rate of biliary obstruction and the need for biliary
intervention before or after GJY or SEMS placement. To compare
survival data, the date of death was noted for patients. Data for
patients who were lost to follow-up were censored on the date of
the last follow-up.
Statistical analysis
Categorical variables are presented as frequency and the corre-
sponding percentage. Continuous variables are summarized using
descriptive statistics including the mean and standard deviation or
themedian and range.We used Fisher’s exact test and theWilcoxon
rank sum test to compare the baseline characteristics and
procedure-related outcomes for the SEMS andGJYgroups. Avalue of
P < 0.05 was considered statistically signiﬁcant. The Kaplan–Meier
method was used to estimate overall survival and recurrence-free
survival. The log-rank test and Cox regression analysis were used
to determine prognostic factors for overall survival and recurrence-
free survival. Variables for which P < 0.15 were included in the
multivariate analysis. SAS software version 9.3 (SAS Institute, Cary,
NC, USA) and TIBCO Sportﬁre S-Plus software version 8.2 (TIBCO
Software, Palo Alto, CA, USA) were used for analyses.
Results
The baseline characteristics of the 334 patients who underwent
GJY (n ¼ 93, 27.8%) or SEMS placement (n ¼ 241, 72.2%) are pre-
sented in Table 1. The proportion of patients who had a baseline
WHO performance status score  2 was signiﬁcantly higher in the
SEMS group (93/146 patients for whom data were available, 63.7%)
than in the GJY group (8/23 patients for whom data were available,
34.7%; P ¼ 0.012). The proportion of patients who received pre-
procedure chemo- or radiotherapy was signiﬁcantly higher in the
SEMS group (168/241 patients, 69.6%) than in the GJY group (46/93
patients, 49.5%; P ¼ 0.0009). The numbers of patients who under-
went SEMS placement or GJY per year during the study period are
shown in Fig. 1. Overall, more patients underwent SEMS placement
than GJY for palliation of malignant GOO symptoms.Oral intake toleration, length of hospital stay, and weight gain
Oral intake was tolerated by 204/241 patients (84.6%) in the
SEMS group and 79/93 patients (84.9%) in the GJY group. There was
no signiﬁcant difference between the groups for ability to tolerate a
liquid diet (P ¼ 0.593) or a soft diet (P ¼ 0.881). The mean times to
liquid diet and soft diet tolerance were signiﬁcantly shorter in the
SEMS group (2.2 3.9 days and 4.8 6.2 days, respectively) than in
the GJY group (8.9  5.6 days and 13.6  20.3 days, respectively;
P¼ 0.0001; Table 2). PatientswhounderwentGJY had a signiﬁcantly
longer hospital stay than patients who underwent SEMS did
(P< 0.0001). The difference inweight gain between the groups at 30
and 60 days was not signiﬁcant (P ¼ 0.472 and 0.973, respectively).Complications
The types of complication experienced by the patients in the
two groups are presented in Table 3. The overall complication rate
was signiﬁcantly higher in the GJY group (10/93 patients, 10.8%)
than in the SEMS group (11/241 patients, 4.5%; P ¼ 0.045). Some
patients in the GJY group experienced severe medical complica-
tions including sepsis, postoperative renal failure, and aspiration
pneumonia. No patients in the SEMS group had any severe medical
complications.Recurrence of symptoms
Recurrence of obstructive symptoms occurred in 33 patients in
the SEMS group and six patients in the GJY group (P ¼ 0.086). The
proportion of patients who required additional interventions for
recurrent obstructive symptoms or stent-related complications was
signiﬁcantly higher in the SEMS group (36/241 patients, 14.9%) than
in the GJY group (3/93 patients, 3.2%; P ¼ 0.002). Of the 36 patients
in the SEMS group who required additional interventions, 19 un-
derwent repeat SEMS placement, six underwent percutaneous
endoscopic gastrostomy tube placement, eight underwent repeat
upper endoscopy, and three underwent GJY. All three patients in
Fig. 1. Use of enteral self-expanding metal stent (SEMS) placement and gastrojejunostomy in our cancer center during 2002–2011.
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percutaneous endoscopic gastrostomy tube placement.
Survival
The median overall survival estimated for all patients was 3.59
months (95% conﬁdence interval [CI] 2.83–4.24 months). The me-
dian follow-up time for surviving patients was 3.19 months (ﬁrst
quartile 0.7 months, third quartile 13.17 months). In the SEMS
group, 209/241 patients died, with amedian overall survival time of
2.4 months (95% CI 2.11–3.06 months). In the GJY group, 59/93
patients died, with a median overall survival time of 10.59 months
(95% CI 7.47–16.84 months). The difference in overall survival be-
tween the groups was signiﬁcant (P < 0.0001). A log-rank test
showed that a good WHO performance score (e.g., <2; P ¼ 0.003),
ability to tolerate a liquid diet (P < 0.0001), ability to tolerate a soft
diet (P < 0.0001), and post-procedure chemo- and radiotherapy
(P < 0.0001) were associated with longer overall survival, whereas
the occurrence of complications was associatedwith shorter overall
survival (P ¼ 0.029). After adjusting for gender effects, WHO per-
formance status score, complications, and ability to tolerate any
diet, multivariate analysis revealed that procedure type, the
occurrence of complications, and post-procedure chemo- or
radiotherapy were independent prognostic factors for overall sur-
vival (Table 4).Table 2 Outcome Comparison for Patients who Underwent Self-expanding
Metal Stent (SEMS) Placement or Gastrojejunostomy (GJY) for Gastric Outlet
Obstruction
Outcome SEMS (n ¼ 241) GJY (n ¼ 93) P
Time to starting a liquid diet (d) 2.2  3.9 8.9  5.6 <0.0001
Time to starting a soft diet (d) 4.8  6.2 13.6  20.3 <0.0001
Duration of hospital stay (d) 12.3  7.9 17.5  9.5 <0.0001
Recurrence 33 (13.7) 6 (6.5) 0.086
Reintervention 36 (14.9) 3 (3.2) 0.002
Complications 11 (4.6) 10 (10.8) 0.045
Data are presented as n (%) or mean  SD.We anticipated that the study would be subject to selection bias
because patients with poor performance status are less likely to
undergo GJY. In addition, performance status scores were missing
for many patients. Hence, we compared overall survival between
patients who underwent chemo- or radiotherapy after stent
placement and patients who underwent GJY with or without
adjuvant therapy. The underlying assumption here was that the
patients undergoing chemo- or radiotherapy after stent placement
would have a performance score comparable to that for patients in
the GJY group. The median overall survival estimated was 10.59
months (95% CI 7.47–16.84 months) for patients who underwent
GJY, 5.07 months (95% CI 3.75–7.07 months) for patients who un-
derwent SEMS placement followed by chemo- and radiotherapy,
and 1.71 months (95% CI 1.48–2.17 months) for patients who un-
derwent SEMS placement only (P < 0.0001; Fig. 2). Univariate Cox
proportional hazards model analysis revealed that patients un-
dergoing SEMS placement only had the highest risk of death
compared to the other two groups [hazard ratio (HR) ¼ 4.65,
P < 0.0001 and HR ¼ 2.37, P < 0.0001]. Patients who received
chemo- and radiotherapy after SEMS placement also had a higher
risk of death compared to GJY patients (HR ¼ 1.95, P ¼ 0.0002).
The median recurrence-free survival time estimated was 2.17
months (95% CI 1.78–2.57 months) for SEMS patients and 10.59
months (95% CI 7.07–16.41 months) for GJY patients. A log-rank test
revealed that a good WHO performance score (e.g., >2; P ¼ 0.004),Table 3 Complications Among Patients who Underwent Self-expanding Metal
Stent (SEMS) Placement or Gastrojejunostomy (GJY) for Gastric Outlet
Obstruction
Complication Number of patients
SEMS GJY
Bleeding 2 0
Stent migration 2 Not applicable
Incomplete stenting 4 Not applicable
Medical complications 3 4
Choledochojejunostomy failure Not applicable 1
Infection 0 5
Table 4 Multivariate Cox Proportional Hazards Regression Analysis of Prognostic Factors for Overall Survival and Recurrence-free Survival Among Patients who
Underwent Self-expanding Metal Stent (SEMS) Placement or Gastrojejunostomy (GJY)
Category Variable Hazard ratio 95% CI P
Overall survival
Treatment GJY versus SEMS 0.227 0.117–0.438 <0.0001
Sex Male versus female 0.842 0.586–1.208 0.35
Performance score >1 versus 1 1.133 0.788–1.629 0.5012
Complications Yes versus no 2.439 1.106–5.376 0.027
Any diet Yes versus no 0.566 0.318–1.007 0.0529
Post-procedure chemo- or radiotherapy Yes versus no 0.466 0.323–0.673 <0.0001
Recurrence-free survival
Treatment GJY versus SEMS 0.203 0.102–0.404 <.0001
Sex Male versus female 0.846 0.587–1.219 0.3691
Performance score >1 versus 1 1.146 0.793–1.657 0.4671
Race White
African American 1.254 0.697–2.255 0.4503
Asian 1.293 0.593–2.819 0.5188
Hispanic 1.17 0.682–2.006 0.5686
Pre-procedure chemo- or radiotherapy Yes versus no 1.116 0.755–1.651 0.5815
Complications Yes versus no 1.99 0.9–4.4 0.0894
Any diet Yes versus no 0.612 0.343–1.092 0.0966
Post-procedure chemo- or radiotherapy Yes versus no 0.563 0.391–0.812 0.0021
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chemo- or radiotherapy (P < 0.0001) were associated with longer
recurrence-free survival. After adjusting for the effects of gender,
performance status score, race, pre-procedure chemo- and radio-
therapy, complications, and the ability to tolerate any diet, multi-
variate analysis revealed that procedure type (HR ¼ 0.203;
P < 0.0001) and post-procedure chemo- or radiotherapy
(HR ¼ 0.56; P ¼ 0.002) were independent prognostic factors for
recurrence-free survival (Table 4).
Biliary obstruction
The rate of biliaryobstructionwas signiﬁcantly higher in the SEMS
group (133/241 patients, 55.2%) than in theGJYgroup (32/93patients,
34.4%; P ¼ 0.0009). This difference was probably related to selection
bias, because patients with a higher tumor burden are likely to
develop simultaneous biliary obstruction and less likely to undergo
GJY. In the SEMS group, 55 patients underwent endoscopic biliary
drainage, 50 patients had percutaneous biliary drainage, 22 patients
had both endoscopic stent placement and percutaneous biliary
drainage, andsixpatientshadnobiliary intervention. In theGJYgroup,Fig. 2. Kaplan–Meier analysis of recurrence-free survival for patients who underwent
gastrojejunostomy, self-expanding metal stent (SEMS) placement, or SEMS placement
followed by chemotherapy or radiation treatment. E/N, events/number at risk; RFS,
recurrence-free survival. Data on post procedure chemo- or radiotherapy was missing
in 4 patients with stent.19 patients underwent endoscopic biliary drainage, four patients had
percutaneous biliary drainage, and nine patients had no intervention.
Discussion
To date, this study is the largest single-center study comparing
outcomes between enteral SEMS placement and GJY for palliation
of malignant GOO symptoms. We found that patients who under-
went SEMS placement tended to start tolerating oral intake sooner,
had fewer complications, and a shorter hospital stay, but had a
higher risk of recurrent obstructive symptoms compared to pa-
tients who underwent GJY. The patients who underwent GJY sur-
vived for longer than patients who underwent SEMS placement
did. As discussed previously, this was most likely due to selection
bias. Patients who have advanced disease and poor performance
status are more likely to undergo SEMS placement.
We compared body weight but found no signiﬁcant difference
between the two groups. Nor did we ﬁnd any signiﬁcant weight
gain within the groups. There are multiple reasons for this trend.
Although many of the patients who underwent these procedures
were able to tolerate a liquid or soft diet, they could not maintain
their nutritional requirements for protein and calorie intake. In
addition, all patients in the study had unresectable cancer and
cancer-related cachexia, which hampers weight gain. Thus,
weight gain could not be used as an outcome for comparison of
the two groups and was not the goal of palliation in these pa-
tients. One of the main objectives in palliating the symptoms of
GOO is to enable patients to enjoy food during their terminal
days.
We found that SEMS placement has been used more frequently
than GJY at our center in recent years to palliate the symptoms of
malignant GOO. The upsurge in this nonsurgical procedure at our
institution may be because of the increasing availability of cancer
care in the community. Many patients who present to our tertiary
care cancer center have already been treated at other facilities and
have exhausted most options for care. By the time these patients
are evaluated in our center, many have a poor performance status
score, which eliminates surgical options.
A total of 48% of our GOO patients presented with a concomitant
biliary obstruction. Many groups have reported their experience
with methods to relieve simultaneous biliary obstruction. Com-
bined placement of biliary and enteral SEMS can be challenging but
is an effective palliative technique.17–23 In our practice, we try to
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do so even in GOO patients who have only a partial biliary
obstruction for two important reasons. First, as demonstrated in
the present and other studies, a large proportion of patients
develop biliary obstruction after SEMS placement or already have
biliary obstructionwhen an intervention for palliation of malignant
GOO symptoms becomes necessary. Second, in the likely event of
biliary obstruction in a patient who has undergone enteral SEMS
placement only, the enteral SEMS could interfere with placement of
a biliary SEMS.
Jeurnink et al proposed that the anticipated survival time should
be considered when deciding between GJYand SEMS placement for
palliation of malignant GOO.3,15 In our study, the median
recurrence-free survival in SEMS patients was 2.17 months. In
general, however, predicting patient survival is difﬁcult. Whether a
patient undergoes SEMS placement or GJY depends on the perfor-
mance status, the presence of comorbid conditions predicting the
likelihood of an uneventful postoperative recovery, and the feasi-
bility of GJY in a patient whose tumor has altered the surrounding
anatomy. We recommend that patients with good performance
statusdpatients for whom surgery is an optiondundergo GJY for
palliation of malignant GOO.
Our study had the inherent limitations of any retrospective
study. WHO performance status scores were not available for all
patients. Because our study included only patients from a tertiary
cancer center, who tend to be sicker and have more advanced
disease than patients in the community do, the study results may
not be generalizable to patients in the community. However, our
study provides data from the largest group of patients with ma-
lignant GOO who underwent SEMS placement or GJY.
In conclusion, we found that compared to GJY, SEMS placement
for palliation of malignant GOO is associated with a faster time to
tolerance of oral intake, fewer complications, and a shorter hospital
stay, but a higher rate of recurrent symptoms of obstruction.
Therefore, patients with an advanced malignancy and a short life
expectancy should undergo duodenal SEMS placement for pallia-
tion of the symptoms of malignant GOO.
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